Zacks Research Upgrades Maximus (NYSE:MMS) to “Hold”

Maximus (NYSE:MMS) was upgraded by investment analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued on Thursday, Zacks reports.

Other equities analysts have also issued reports about the company. Wall Street Zen lowered Maximus from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Maximus in a report on Monday, August 17th. Two research analysts have rated the stock with a Hold rating, According to data from MarketBeat, the company currently has an average rating of “Hold”.

Maximus Stock Down 1.5%

Maximus stock opened at $52.72 on Thursday. Maximus has a fifty-two week low of $51.04 and a fifty-two week high of $100.00. The stock has a market cap of $2.76 billion, a PE ratio of 7.79 and a beta of 0.59. The firm’s 50-day simple moving average is $57.31 and its 200 day simple moving average is $60.29. The company has a debt-to-equity ratio of 0.90, a quick ratio of 2.42 and a current ratio of 2.42.

Maximus (NYSE:MMS) last issued its quarterly earnings data on Thursday, August 6th. The health services provider reported $2.22 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.21 by $0.01. The business had revenue of $1.28 billion during the quarter, compared to the consensus estimate of $1.33 billion. Maximus had a net margin of 7.07% and a return on equity of 24.91%. The firm’s quarterly revenue was down 5.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.16 EPS. Maximus has set its FY 2026 guidance at 7.900-8.200 EPS. Research analysts predict that Maximus will post 8.03 EPS for the current fiscal year.

Insiders Place Their Bets

In other Maximus news, insider Michelle Link sold 3,208 shares of the business’s stock in a transaction dated Thursday, October 1st. The shares were sold at an average price of $54.23, for a total value of $173,969.84. Following the transaction, the insider directly owned 13,881 shares in the company, valued at $752,766.63. The trade was a 18.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.80% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Maximus

Several large investors have recently modified their holdings of MMS. Sequoia Financial Advisors LLC bought a new position in Maximus during the second quarter valued at $294,000. WINTON GROUP Ltd raised its stake in shares of Maximus by 1,992.2% in the second quarter. WINTON GROUP Ltd now owns 83,687 shares of the health services provider’s stock valued at $4,499,000 after buying an additional 79,687 shares during the period. Engineers Gate Manager LP purchased a new position in shares of Maximus during the 2nd quarter valued at $2,075,000. Integrated Wealth Concepts LLC purchased a new position in shares of Maximus during the 2nd quarter valued at $34,000. Finally, Squarepoint Ops LLC grew its stake in shares of Maximus by 723.0% during the 2nd quarter. Squarepoint Ops LLC now owns 219,301 shares of the health services provider’s stock worth $11,790,000 after acquiring an additional 192,655 shares during the period. Hedge funds and other institutional investors own 97.21% of the company’s stock.

Maximus Company Profile

Maximus, Inc (NYSE:MMS) is a provider of government services and technology-enabled solutions. The company partners with federal, state, provincial and local governments to administer public programs, improve service delivery and support interactions between governments and the people they serve.

Its business activities include health and human services administration, employment and workforce services, child support and eligibility services, customer contact centers, program management, consulting and digital transformation.